TD Cowen analyst Ritu Baral downgraded Spero Therapeutics (NASDAQ: SPRO) from Buy to Hold.The analyst comments: "We are downgrading SPRO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE